Printer Friendly

Diamics Inc.'s Proprietary Cervical Cancer Screening System to Be Presented at AACC Clinical Lab Expo.

NOVATO, Calif. -- Diamics Inc., a San Francisco Bay area medical device and diagnostics company, today announced it will present several scientific posters at the annual American Association for Clinical Chemistry (AACC) meeting describing the company's proprietary cervical cancer screening system. The posters will be on display at the Diamics exhibit (#2466).

The system, called C-MAP, is designed to be a faster, less expensive and more accurate way to screen for cervical cancer than Pap tests and other current screening approaches. It examines the behavior of groups of cells within discrete areas of the cervix, allowing lesions to be effectively analyzed in situ. Because results are quickly available, the screening system will allow physicians to "see and treat" patients during a single visit.

The novel and economical screening system requires virtually no medical infrastructure and is expected to have widespread use in the developing world, where more than 500,000 new cases of cervical cancer are diagnosed each year. The actual number is thought to be much higher. Worldwide, cervical cancer is the second most common woman's cancer after cancer of the breast.

C-MAP, which is being developed by Diamics, employs fractional histology, or the microscopic examination of tissue elements characteristic of the disease process. Tissue is collected from the entire cervix in a single process, utilizing a patented single-use collector which captures a 360-degree view of the cervix and transfers it to a slide. The tissue then is exposed to antibodies and placed in a proprietary optical scanner which generates a map of the cervix showing the location of precancerous lesions.

"The C-MAP system will be a valuable addition to medical facilities throughout the world and will help save many lives. It will be less costly to deploy and is designed to provide an earlier and more accurate detection of cervical cancer than Pap and other screening approaches," said Peter Gombrich, CEO, Diamics Inc.

The posters on display at AACC describe the unique molecular-based cervical cancer screening approach, the fractional histological cervical collector, and the development and testing of the screening system.

About Diamics Inc.

Diamics Inc. is a privately owned medical device and diagnostics company located in Novato, Calif. The company is committed to developing, manufacturing, and marketing cost-effective, molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Diamics has a mature management team with an extensive track record in the medical device and diagnostics industries. The company's goals are to help medical personnel worldwide improve lives and to create value for investors, employees and all who use and benefit from its proprietary technology. Please visit www.diamics.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 19, 2006
Words:436
Previous Article:Ad Agency 760 Media Retained by Land Developer; Launches Lead Generation Campaign for Baja Development.
Next Article:Start the School Year Right by Shopping Smart: MMI Offers Back-to-School Shopping Tips to Save Budgets.
Topics:


Related Articles
DPC TO DEBUT IMMULITE 1000 AUTOMATED IMMUNOASSAY SYSTEM.
Increasing organizational capacity for breast and cervical cancer screening of AAPI women.
FREE HEALTH SCREENINGS OFFERED AT LOCAL EXPO.
RECAF BLOOD TEST DETECTS 92% OF CERVICAL CANCERS.
Molecular Diagnostics Congratulates Merck Scientists on the Advancement of Their New HPV Vaccine.
Seminar spotlights tests for cancer-causing virus.
Studies Presented at ASCCP Biennial Meeting Demonstrate Accuracy and Cost-Effectiveness of ThinPrep(R) Imaging System.
Diamics Submits 510k to FDA for Unique Cervical Collection Device.
mtm Laboratories Extends Marketing & Sales Team; Felix Dross and Jan Wauters to Join.
Cytyc Announces Multi-Year Contract Extension with LabCorp for ThinPrep(R) Imaging System.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters